Attached files

file filename
8-K - FORM 8-K - Shire plcdp22138_8k.htm
 
Exhibit 99.01
 
Press Release
www.shire.com
 
   
 
Notification of major interests in shares

April 19, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY)
 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
     
An event changing the breakdown of voting rights
 
Other (please specify):
     

3. Full name of person(s) subject to the notification obligation:
FMR LLC
4. Full name of shareholder(s) (if different from 3.):
 
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
14 April 2011
6. Date on which issuer notified:
18 April 2011
7. Threshold(s) that is/are crossed or reached:
 
5%
8. Notified details:
     

A: Voting rights attached to shares

 
 
Class/type of shares
 if possible using the ISIN CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
     
Direct
Indirect
Direct
Indirect
Direct
Indirect
 JE00B2QKY057
27,810,001
27,810,001
 
28,129,636
 
28,129,636
 
5%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if  the instrument
is exercised/converted
% of voting
rights
n/a
     
     
     
     

Total (A+B)
 
Number of voting rights
% of voting rights
28,129,636
5%
   
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 

 
 
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

FMR LLC is the parent holding company of Fidelity Management & Research Company (FMRCO), investment manager for US mutual funds, FIL Management Trust Company (FMTC), Pyramis Global Advisors Trust Company (PGATC), a US state chartered bank which acts as a trustee or investment manager of various pension and trust accounts Pyramis Global Advisors LLC (PGALLC) and Pyramis Trust Company (PTC).

SHARES HELD
NOMINEE
MANAGEMENT COMPANY
170,777
BANK OF NEW YORK
FMRCO
51,000
BROWN BROTHERS HARRIMAN AND CO
FMR
15,208,757
BROWN BROTHERS HARRIMAN AND CO
FMRCO
22,900
BROWN BROTHERS HARRIMAN AND CO
PTC
54,586
CIBC MELLON TRUST
FCL
1,590,900
JPMORGAN CHASE BANK
FMR
3,577,080
JPMORGAN CHASE BANK
FMRCO
20,400
JPMORGAN CHASE BANK
FMTC
69,799
JPMORGAN CHASE BANK
FMR
388,800
JPMORGAN CHASE BANK
PTC
87,700
MELLON BANK N.A.
FMRCO
86,343
MELLON BANK N.A.
FMTC
203,400
MELLON BANK N.A.
PTC
18,500
NORTHERN TRUST CO
FMRCO
117,304
NORTHERN TRUST CO
FMTC
243,754
STATE STREET BANK AND TR CO
FICL
18,018
STATE STREET BANK AND TR CO
FMR
1,292,603
STATE STREET BANK AND TR CO
FMRCO
335,584
STATE STREET BANK AND TR CO
FMTC
310,951
STATE STREET BANK AND TR CO
PTC
146,321
CIBC MELLON TRUST (C)
FCL
159,000
ROYAL TRUST-TORONTO
FCL
1,405,800
CITIBANK NA (C)
FMR
28,800
MELLON BANK NA (C)
PTC
2,309,901
NORTHERN TRUST CO (C)
FMR
29,200
BANK OF NEW YORK MELLON
PTC
66,200
NATIONAL BANK TRUST (C)
FCL
32,300
ROYAL TRUST- TORONTO (C)
FCL
31,407
ROYAL BANK OF CANADA ©
PTC
50,440
US BANK NA (C)
PTC
1,111
N/A
N/A

Proxy Voting:

10. Name of the proxy holder:
FMR LLC
11. Number of voting rights proxy holder will acquire:
319,635
12. Date on which proxy holder will acquire voting rights:
14 April 2011

13. Additional information:
Notification using the total voting rights figures of
562,241,550
 
14. Contact name:
Philip Alexander
15. Contact telephone number:
Fil-regreporting@fil.com – 01737 834624
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 

 
 
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, +44 1256 894746
 
For further information please contact:

Investor Relations
Eric Rojas
+1 781 482 0999
     
Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX